PYOTT DAVID E I sold $366K of ALNY
PYOTT DAVID E I sold 1,222 shares of ALNYLAM PHARMACEUTICALS, INC. (ALNY) at $299.87 ($0.37M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides incremental information about insider positioning but does not introduce new company fundamentals (no earnings, trial, or regulatory update).
Market read
Traders may monitor for follow-on insider selling, but this specific filing is unlikely to drive a major repricing by itself.
What to watch
The filing does not reveal motivation; traders should compare with prior insider activity cadence and total insider net selling over recent quarters.
Background
SEC Form 4 discloses insider transactions (director/officer/10% owner) and includes whether trades were executed under a pre-arranged 10b5-1 plan.
Ticker impact
Alnylam director David E. Pyott sold 1,222 shares in an open-market transaction at ~$299.87 on a 10b5-1 plan, per Form 4.
Low likelihood of a sustained price move; any reaction is likely brief unless follow-on selling accelerates.
Form 4 shows a pre-arranged 10b5-1 plan and a relatively small share count versus typical daily liquidity, so the signal is usually muted.
Market effects
Minimal; single-company insider transaction without new clinical/regulatory or deal information.
None specific.
None specific.
Counterpoint
Even with a 10b5-1 plan, repeated or larger-than-usual director sales can precede periods of heightened risk perception.
Key entities
- issuerALNY
Alnylam Pharmaceuticals, Inc.; subject of the Form 4 insider sale disclosure.
- directorPYOTT DAVID E I
Director who sold 1,222 shares under a 10b5-1 plan.
